Oncoanalyser

<h1> <picture> <source media="(prefers-color-scheme: dark)" srcset="docs/images/nf-core-oncoanalyser_logo_dark.png"> <img alt="nf-core/oncoanalyser" src="docs/images/nf-core-oncoanalyser_logo_light.png"> </picture> </h1>

Introduction

nf-core/oncoanalyser is a Nextflow pipeline for the comprehensive analysis of cancer DNA and RNA sequencing data using the WiGiTS toolkit from the Hartwig Medical Foundation. The pipeline supports a wide range of experimental setups:

• FASTQ, BAM, and / or CRAM input files
• WGS (whole genome sequencing), WTS (whole transcriptome sequencing), and targeted / panel sequencing¹
• Paired tumor / normal and tumor-only samples, and support for donor samples for further normal subtraction
• Purity estimate for longitudinal samples using genomic features of the primary sample from the same patient²
• UMI (unique molecular identifier) processing supported for DNA sequencing data
• Most GRCh37 and GRCh38 reference genome builds

_{¹ built-in support for the TSO500 panel with other panels and exomes requiring creation of custom panel reference data} <br /> _{² for example a primary WGS tissue biospy and longitudinal low-pass WGS ccfDNA sample taken from the same patient}

Pipeline overview

<p align="center"><img src="docs/images/oncoanalyser_pipeline.png"></p>

The pipeline mainly uses tools from WiGiTS, as well as some other external tools. There are several workflows available in oncoanalyser and the tool information below primarily relates to the wgts and targeted analysis modes.

[!NOTE] Due to the limitations of panel data, certain tools (indicated with * below) do not run in targeted mode.

• Read alignment: BWA-MEM2 (DNA), STAR (RNA)
• Read post-processing: REDUX (DNA), Picard MarkDuplicates (RNA)
• SNV, MNV, INDEL calling: SAGE, PAVE
• SV calling: ESVEE
• CNV calling: AMBER, COBALT, PURPLE
• SV and driver event interpretation: LINX
• RNA transcript analysis: ISOFOX
• Oncoviral detection: VIRUSbreakend*, VirusInterpreter*
• Telomere characterisation: TEAL*
• Immune analysis: LILAC, CIDER, NEO*
• Mutational signature fitting: SIGS*
• HRD prediction: CHORD*
• Tissue of origin prediction: CUPPA*
• Pharmacogenomics: PEACH
• Summary report: ORANGE, linxreport

For the purity_estimate mode, several of the above tools are run with adjusted configuration in addition to the following.

• Tumor fraction estimation: WISP

Usage

[!NOTE] If you are new to Nextflow and nf-core, please refer to this page on how to set-up Nextflow. Make sure to test your setup with -profile test before running the workflow on actual data.

Create a samplesheet with your inputs (WGS/WTS BAMs in this example):

group_id,subject_id,sample_id,sample_type,sequence_type,filetype,filepath
PATIENT1_WGTS,PATIENT1,PATIENT1-N,normal,dna,bam,/path/to/PATIENT1-N.dna.bam
PATIENT1_WGTS,PATIENT1,PATIENT1-T,tumor,dna,bam,/path/to/PATIENT1-T.dna.bam
PATIENT1_WGTS,PATIENT1,PATIENT1-T-RNA,tumor,rna,bam,/path/to/PATIENT1-T.rna.bam

Launch oncoanalyser:

nextflow run nf-core/oncoanalyser \
  -profile <docker/singularity/.../institute> \
  -revision 2.3.0 \
  --mode <wgts/targeted> \
  --genome <GRCh37_hmf/GRCh38_hmf> \
  --input samplesheet.csv \
  --outdir output/

[!WARNING] Please provide pipeline parameters via the CLI or Nextflow -params-file option. Custom config files including those provided by the -c Nextflow option can be used to provide any configuration except for parameters; see docs.

For more details and further functionality, please refer to the usage documentation and the parameter documentation.

Pipeline output

To see the results of an example test run with a full size dataset refer to the results tab on the nf-core website pipeline page. For more details about the output files and reports, please refer to the output documentation.

Version information

Extended support

As oncoanalyser is used in clinical settings and subject to accreditation standards in some instances, there is a need for long-term stability and reliability for feature releases in order to meet operational requirements. This is accomplished through long-term support of several nominated feature releases, which all receive bug fixes and security fixes during the period of extended support.

Each release that is given extended support is allocated a separate long-lived git branch with the 'stable' prefix, e.g. stable/1.2.x, stable/1.5.x. Feature development otherwise occurs on the dev branch with stable releases pushed to master.

Versions nominated to have current long-term support:

• TBD

Known issues

Please refer to this page for details regarding any known issues.

Credits

The oncoanalyser pipeline was written and is maintained by Stephen Watts (@scwatts) from the Genomics Platform Group at the University of Melbourne Centre for Cancer Research.

We thank the following organisations and peo